Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcept's NDA Intermission For Insomnia Drug Intermezzo Set To End In First Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Results from a driving impairment study strengthen the case for approval, the company says.
Advertisement

Related Content

Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Insomnia Drug Development Programs Must Include Driving Studies, FDA Says
Second Intermezzo "Complete Response" Threatens Transcept's Partnership Payments
Second Intermezzo "Complete Response" Threatens Transcept's Partnership Payments
FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo
FDA Holds To High Standards For Insomnia Drugs With Second “Complete Response” For Transcept’s Intermezzo

Topics

Advertisement
UsernamePublicRestriction

Register

PS071327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel